| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics |
Section of Cellular and Molecular Pharmacology, Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center [Z. S., A. A., D. S., Y-X. L., P. H., W. P.], and The University of Texas Graduate School of Biomedical Sciences [Z. S.], Houston, Texas 77030
The mechanisms of resistance to nucleoside analogues established in preclinical models are rarely found in primary tumors resistant to therapy with these agents. We tested the hypothesis that cells sense sublethal incorporation of analogues into DNA during replication and react by arresting further DNA synthesis and cell cycle progression. After removal of drug, cells may be able to repair damaged DNA and continue proliferation, thus escaping nucleoside analogue toxicity. As a corollary, we evaluated whether dysregulation of this mechanism causes cell death. Using gemcitabine as a model of S-phase-specific nucleoside analogues in human acute myelogenous leukemia ML-1 cells, we found that DNA synthesis decreased, cells arrested in S-phase transit, and 60–70% of the population accumulated in S-phase in response to cytostatic conditions. Proliferation continued after washing the cells into drug-free medium. S-phase-arrested cells were then treated with otherwise nontoxic concentrations of UCN-01, which caused rapid onset of apoptosis without cell cycle progression specifically in cells with an S-phase DNA content. Thus, S-phase arrest by nucleoside analogues sensitizes cells to UCN-01, which appears to activate signaling for death mechanisms and/or inhibit survival pathways. These results differ from those in cells arrested at the G2 checkpoint, in which UCN-01 abrogates cell cycle arrest, permitting cells to progress in the cell cycle before apoptosis.
This article has been cited by other articles:
|
|
 |
|
  C. Cavelier, C. Didier, N. Prade, V. Mansat-De Mas, S. Manenti, C. Recher, C. Demur, and B. Ducommun Constitutive Activation of the DNA Damage Signaling Pathway in Acute Myeloid Leukemia with Complex Karyotype: Potential Importance for Checkpoint Targeting Therapy Cancer Res., November 15, 2009; 69(22): 8652 - 8661. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. F. Krynetskaia, M. S. Phadke, S. H. Jadhav, and E. Y. Krynetskiy Chromatin-associated proteins HMGB1/2 and PDIA3 trigger cellular response to chemotherapy-induced DNA damage Mol. Cancer Ther., April 1, 2009; 8(4): 864 - 872. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Ewald, D. Sampath, and W. Plunkett ATM and the Mre11-Rad50-Nbs1 Complex Respond to Nucleoside Analogue-Induced Stalled Replication Forks and Contribute to Drug Resistance Cancer Res., October 1, 2008; 68(19): 7947 - 7955. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Galvez-Peralta, N. T. Dai, D. A. Loegering, K. S. Flatten, S. L. Safgren, J. M. Wagner, M. M. Ames, L. M. Karnitz, and S. H. Kaufmann Overcoming S-Phase Checkpoint-Mediated Resistance: Sequence-Dependent Synergy of Gemcitabine and 7-Ethyl-10-hydroxycamptothecin (SN-38) in Human Carcinoma Cell Lines Mol. Pharmacol., September 1, 2008; 74(3): 724 - 735. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ganzinelli, L. Carrassa, F. Crippa, M. Tavecchio, M. Broggini, and G. Damia Checkpoint Kinase 1 Down-Regulation by an Inducible Small Interfering RNA Expression System Sensitized In vivo Tumors to Treatment with 5-Fluorouracil Clin. Cancer Res., August 15, 2008; 14(16): 5131 - 5141. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Wang, X. Liu, A. Matsuda, and W. Plunkett Repair of 2'-C-Cyano-2'-Deoxy-1-{beta}-D-arabino-Pentofuranosylcytosine-Induced DNA Single-Strand Breaks by Transcription-Coupled Nucleotide Excision Repair Cancer Res., May 15, 2008; 68(10): 3881 - 3889. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Seiler, C. Conti, A. Syed, M. I. Aladjem, and Y. Pommier The Intra-S-Phase Checkpoint Affects both DNA Replication Initiation and Elongation: Single-Cell and -DNA Fiber Analyses Mol. Cell. Biol., August 15, 2007; 27(16): 5806 - 5818. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. N. Tse, R. Carvajal, and G. K. Schwartz Targeting Checkpoint Kinase 1 in Cancer Therapeutics Clin. Cancer Res., April 1, 2007; 13(7): 1955 - 1960. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Ewald, D. Sampath, and W. Plunkett H2AX phosphorylation marks gemcitabine-induced stalled replication forks and their collapse upon S-phase checkpoint abrogation Mol. Cancer Ther., April 1, 2007; 6(4): 1239 - 1248. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Yao, B. Weigel, and J. Kersey Synergism between Etoposide and 17-AAG in Leukemia Cells: Critical Roles for Hsp90, FLT3, Topoisomerase II, Chk1, and Rad51 Clin. Cancer Res., March 1, 2007; 13(5): 1591 - 1600. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Kranz and M. Dobbelstein Nongenotoxic p53 Activation Protects Cells against S-Phase-Specific Chemotherapy Cancer Res., November 1, 2006; 66(21): 10274 - 10280. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Sampath, J. Cortes, Z. Estrov, M. Du, Z. Shi, M. Andreeff, V. Gandhi, and W. Plunkett Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial Blood, March 15, 2006; 107(6): 2517 - 2524. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Crescenzi, A. Chiaviello, G. Canti, E. Reddi, B. M. Veneziani, and G. Palumbo Low doses of cisplatin or gemcitabine plus Photofrin/photodynamic therapy: Disjointed cell cycle phase-related activity accounts for synergistic outcome in metastatic non-small cell lung cancer cells (H1299). Mol. Cancer Ther., March 1, 2006; 5(3): 776 - 785. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Granville, R. M. Memmott, J. J. Gills, and P. A. Dennis Handicapping the Race to Develop Inhibitors of the Phosphoinositide 3-Kinase/Akt/Mammalian Target of Rapamycin Pathway Clin. Cancer Res., February 1, 2006; 12(3): 679 - 689. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. K. Schwartz and M. A. Shah Targeting the Cell Cycle: A New Approach to Cancer Therapy J. Clin. Oncol., December 20, 2005; 23(36): 9408 - 9421. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Karnitz, K. S. Flatten, J. M. Wagner, D. Loegering, J. S. Hackbarth, S. J. H. Arlander, B. T. Vroman, M. B. Thomas, Y.-U. Baek, K. M. Hopkins, et al. Gemcitabine-Induced Activation of Checkpoint Signaling Pathways That Affect Tumor Cell Survival Mol. Pharmacol., December 1, 2005; 68(6): 1636 - 1644. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Mesa, D. Loegering, H. L. Powell, K. Flatten, S. J. H. Arlander, N. T. Dai, M. P. Heldebrant, B. T. Vroman, B. D. Smith, J. E. Karp, et al. Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine Blood, July 1, 2005; 106(1): 318 - 327. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Kortmansky, M. A. Shah, A. Kaubisch, A. Weyerbacher, S. Yi, W. Tong, R. Sowers, M. Gonen, E. O'Reilly, N. Kemeny, et al. Phase I Trial of the Cyclin-Dependent Kinase Inhibitor and Protein Kinase C Inhibitor 7-Hydroxystaurosporine in Combination With Fluorouracil in Patients With Advanced Solid Tumors J. Clin. Oncol., March 20, 2005; 23(9): 1875 - 1884. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Hahn, W. Li, C. Yu, M. Rahmani, P. Dent, and S. Grant Rapamycin and UCN-01 synergistically induce apoptosis in human leukemia cells through a process that is regulated by the Raf-1/MEK/ERK, Akt, and JNK signal transduction pathways Mol. Cancer Ther., March 1, 2005; 4(3): 457 - 470. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. N. Tse and G. K. Schwartz Potentiation of Cytotoxicity of Topoisomerase I Poison by Concurrent and Sequential Treatment with the Checkpoint Inhibitor UCN-01 Involves Disparate Mechanisms Resulting in Either p53-Independent Clonogenic Suppression or p53-Dependent Mitotic Catastrophe Cancer Res., September 15, 2004; 64(18): 6635 - 6644. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Loegering, S. J. H. Arlander, J. Hackbarth, B. T. Vroman, P. Roos-Mattjus, K. M. Hopkins, H. B. Lieberman, L. M. Karnitz, and S. H. Kaufmann Rad9 Protects Cells from Topoisomerase Poison-induced Cell Death J. Biol. Chem., April 30, 2004; 279(18): 18641 - 18647. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. H. Arlander, A. K. Eapen, B. T. Vroman, R. J. McDonald, D. O. Toft, and L. M. Karnitz Hsp90 Inhibition Depletes Chk1 and Sensitizes Tumor Cells to Replication Stress J. Biol. Chem., December 26, 2003; 278(52): 52572 - 52577. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Jia, C. Yu, M. Rahmani, G. Krystal, E. A. Sausville, P. Dent, and S. Grant Synergistic antileukemic interactions between 17-AAG and UCN-01 involve interruption of RAF/MEK- and AKT-related pathways Blood, September 1, 2003; 102(5): 1824 - 1832. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. O. Rodriguez Jr, C. M. Stellrecht, and V. Gandhi Mechanisms for T-cell selective cytotoxicity of arabinosylguanine Blood, September 1, 2003; 102(5): 1842 - 1848. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Wang, Z. Wang, and S. Grant Bryostatin 1 and UCN-01 Potentiate 1-beta -D-Arabinofuranosylcytosine-Induced Apoptosis in Human Myeloid Leukemia Cells through Disparate Mechanisms Mol. Pharmacol., January 1, 2003; 63(1): 232 - 242. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Dai, T. H. Landowski, S. T. Rosen, P. Dent, and S. Grant Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and -resistant myeloma cells through an IL-6-independent mechanism Blood, October 16, 2002; 100(9): 3333 - 3343. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Eastman, E. A. Kohn, M. K. Brown, J. Rathman, M. Livingstone, D. H. Blank, and G. W. Gribble A Novel Indolocarbazole, ICP-1, Abrogates DNA Damage-induced Cell Cycle Arrest and Enhances Cytotoxicity: Similarities and Differences to the Cell Cycle Checkpoint Abrogator UCN-01 Mol. Cancer Ther., October 1, 2002; 1(12): 1067 - 1078. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Sampath, Z. Shi, and W. Plunkett Inhibition of Cyclin-Dependent Kinase 2 by the Chk1-Cdc25A Pathway during the S-Phase Checkpoint Activated by Fludarabine: Dysregulation by 7-Hydroxystaurosporine Mol. Pharmacol., September 1, 2002; 62(3): 680 - 688. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Kohn, N. D. Ruth, M. K. Brown, M. Livingstone, and A. Eastman Abrogation of the S Phase DNA Damage Checkpoint Results in S Phase Progression or Premature Mitosis Depending on the Concentration of 7-Hydroxystaurosporine and the Kinetics of Cdc25C Activation J. Biol. Chem., July 12, 2002; 277(29): 26553 - 26564. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Yamauchi, M. J. Keating, and W. Plunkett UCN-01 (7-Hydroxystaurosporine) Inhibits DNA Repair and Increases Cytotoxicity in Normal Lymphocytes and Chronic Lymphocytic Leukemia Lymphocytes Mol. Cancer Ther., February 1, 2002; 1(4): 287 - 294. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Dai, C. Yu, V. Singh, L. Tang, Z. Wang, R. McInistry, P. Dent, and S. Grant Pharmacological Inhibitors of the Mitogen-activated Protein Kinase (MAPK) Kinase/MAPK Cascade Interact Synergistically with UCN-01 to Induce Mitochondrial Dysfunction and Apoptosis in Human Leukemia Cells Cancer Res., July 1, 2001; 61(13): 5106 - 5115. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
